Dignitana AB

Equities

DIGN

SE0002108001

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets 04:57:54 2024-04-26 am EDT			5-day change	1st Jan Change
1.615 ^SEK	-3.58%		-2.12%	-25.92%

Apr. 24	Dignitana AB Announces Chief Executive Officer Changes , Effective May 2, 2024	CI
Apr. 04	Dignitana Raises SEK19 Million via Rights Issue of Shares	MT

Dignitana - Focus on the Opportunities

November 19, 2021 at 03:00 am EST

Redeye continues to view Dignitana as very compelling long term growth case. The results in the Q3 did not show any real surprises. The positive outcome of the reimbursement levels in the US will drive growth in 2022 and forward. We adjust our near-term estimates and have increased our long-term growth estimates slightly. Consequently, we raise our fair value range to SEK 8 –28 per share with a base case of SEK 18 (16) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Dignitana AB

Dignitana AB Announces Chief Executive Officer Changes , Effective May 2, 2024	Apr. 24	CI
Dignitana Raises SEK19 Million via Rights Issue of Shares	Apr. 04	MT
Dignicap Delta Study Underway in Brindisi, Italy	Mar. 07	CI
Sweden's Dignitana to Raise SEK19 Million via Rights Issues, Secures SEK5 Million Bridge Loan	Feb. 22	MT
Dignitana AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Dignitana AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Dignitana Receives Japanese Market Approval for Medical Device for Cancer Patients	Feb. 12	MT
Dignitana Announces DigniCap Delta Receives Market Approval in Japan	Feb. 12	CI
Dignitana Announces Preliminary Results of DigniCap Delta Study Demonstrates 79% Efficacy	Jan. 16	CI
Dignitana Signs Exclusive Distribution Deal with OncoMedical	Jan. 15	MT
Dignitana AB Signs OncoMedical AG for Distribution in Switzerland and Liechtenstein	Jan. 15	CI
Dignitana AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Dignitana AB Appoints Nomination Committee	Nov. 07	CI
Dignitana Signs Sales & Marketing Deal With US-based InfuSystem; Shares Drop	23-10-04	MT
Dignitana AB Announces Sales and Marketing Partnership with InfuSystem Holdings, Inc. to Provide Scalp Cooling Systems in the United States	23-10-04	CI
Palmetto GBA Medicare Contractor Backs Dignitana's Scalp Cooling Solution for Cancer Patients	23-10-03	MT
Dignitana AB Announces Palmetto GBA Approves First Local Coverage Determination for Scalp Cooling Therapy	23-10-03	CI
Dignitana AB Long-Term Study Demonstrates Safety and Efficacy of Scalp Cooling to Reduce Chemo Hair Loss	23-08-17	CI
Dignitana AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Dignitana Expands Oneservice Collaboration to Include DigniCap Delta	23-08-17	MT
Dignitana AB Expands Customer Service Coverage in Europe with Oneservice Partnership	23-08-17	CI
Dignitana to Deliver Improved Scalp Cooling Technology to Minimize Chemotherapy-induced Hair Loss in Mexico	23-08-17	MT
Dignitana AB Expands Partnership with Celeritas to Improve Scalp Cooling Technology Available in Mexico	23-08-16	CI
Dignitana AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Dignitana to Bring Scalp Cooling System to Hong Kong, Macao via Science International	23-03-22	MT

Chart Dignitana AB

Duration

Period

More charts

Company Profile

Dignitana AB is a Sweden-based medical technology company. It develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The Company focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patientâs head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. It has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-22 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Dignitana AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
DIGNITANA AB	-25.92%	10.82M
SHOCKWAVE MEDICAL, INC.	+72.64%	12.34B
PENUMBRA, INC.	-18.30%	7.96B
MASIMO CORPORATION	+15.38%	7.16B
GETINGE AB	+5.26%	5.72B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+6.51%	5.03B
APT MEDICAL INC.	+21.99%	4.35B
ASAHI INTECC CO., LTD.	-21.67%	3.99B
INARI MEDICAL, INC.	-41.36%	2.21B
SKAN GROUP AG	+0.37%	2.01B

Medical Equipment